Total Payments
$255,784
2024 Payments
$8,126
Companies
40
Transactions
1,334
Medicare Patients
6,671
Medicare Billing
$744,214
Payment Breakdown by Category
Other$154,486 (60.4%)
Consulting$42,359 (16.6%)
Food & Beverage$23,973 (9.4%)
Travel$23,810 (9.3%)
Research$10,926 (4.3%)
Education$231.35 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $149,438 | 92 | 58.4% |
| Consulting Fee | $42,359 | 24 | 16.6% |
| Food and Beverage | $23,973 | 1,098 | 9.4% |
| Travel and Lodging | $23,810 | 85 | 9.3% |
| Unspecified | $10,926 | 5 | 4.3% |
| Honoraria | $5,048 | 3 | 2.0% |
| Education | $231.35 | 27 | 0.1% |
Payments by Type
General
$244,858
1,329 transactions
Research
$10,926
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $194,110 | 309 | $0 (2024) |
| Janssen Biotech, Inc. | $11,540 | 141 | $0 (2024) |
| Eli Lilly and Company | $10,926 | 5 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $6,327 | 22 | $0 (2024) |
| Horizon Pharma plc | $5,710 | 53 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $5,026 | 96 | $0 (2024) |
| Amgen Inc. | $4,287 | 126 | $0 (2024) |
| PFIZER INC. | $3,269 | 88 | $0 (2024) |
| ABBVIE INC. | $2,044 | 97 | $0 (2024) |
| Kyowa Kirin, Inc. | $1,918 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,126 | 194 | Kyowa Kirin, Inc. ($1,918) |
| 2023 | $37,010 | 191 | Lilly USA, LLC ($27,248) |
| 2022 | $31,943 | 161 | Lilly USA, LLC ($22,609) |
| 2021 | $18,722 | 114 | Lilly USA, LLC ($13,012) |
| 2020 | $25,635 | 53 | Lilly USA, LLC ($12,248) |
| 2019 | $86,824 | 237 | Lilly USA, LLC ($82,569) |
| 2018 | $41,275 | 198 | Lilly USA, LLC ($36,129) |
| 2017 | $6,249 | 186 | Horizon Pharma plc ($2,954) |
All Payment Transactions
1,334 individual payment records from CMS Open Payments — Page 1 of 54
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Lilly USA, LLC | TALTZ (Drug), OLUMIANT, ZEPBOUND | Food and Beverage | In-kind items and services | $28.29 | General |
| Category: Immunology | ||||||
| 12/19/2024 | Lilly USA, LLC | TALTZ (Drug), OLUMIANT, ZEPBOUND | Food and Beverage | In-kind items and services | $2.87 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $9.76 | General |
| Category: Dermatology | ||||||
| 12/17/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: Inflammation | ||||||
| 12/11/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $25.49 | General |
| Category: Inflammation | ||||||
| 12/10/2024 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $9.66 | General |
| 12/09/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $6.76 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $8.00 | General |
| Category: Immunology | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $23.18 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/03/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $18.58 | General |
| Category: IMMUNOLOGY | ||||||
| 11/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $31.71 | General |
| Category: RESPIRATORY | ||||||
| 11/22/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $7.55 | General |
| Category: Immunology | ||||||
| 11/21/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $33.91 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $29.87 | General |
| Category: Inflammation | ||||||
| 11/18/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $10.87 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $25.10 | General |
| Category: Dermatology | ||||||
| 11/07/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $29.51 | General |
| Category: IMMUNOLOGY | ||||||
| 11/06/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $26.16 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/06/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $18.53 | General |
| Category: IMMUNOLOGY | ||||||
| 11/06/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $10.59 | General |
| Category: Immunology | ||||||
| 11/06/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $4.68 | General |
| Category: Immunology | ||||||
| 11/05/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $29.42 | General |
| Category: IMMUNOLOGY | ||||||
| 11/05/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $25.10 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 11/04/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Consulting Fee | Cash or cash equivalent | $1,725.00 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 11/04/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $26.40 | General |
| Category: Inflammation/Rare Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | Eli Lilly and Company | $10,641 | 3 |
| A PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | Eli Lilly and Company | $285.00 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 31 | 1,898 | 5,827 | $601,400 | $196,428 |
| 2022 | 32 | 1,678 | 4,429 | $543,080 | $194,251 |
| 2021 | 29 | 1,589 | 4,029 | $478,480 | $198,857 |
| 2020 | 31 | 1,506 | 3,356 | $372,160 | $154,678 |
Total Patients
6,671
Total Services
17,641
Medicare Billing
$744,214
Procedure Codes
123
All Medicare Procedures & Services
123 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 188 | 715 | $164,450 | $67,625 | 41.1% |
| 76881 | Complete ultrasound scan of joint | Office | 2023 | 153 | 857 | $197,430 | $35,834 | 18.2% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2023 | 58 | 161 | $36,820 | $14,360 | 39.0% |
| 86235 | Measurement of antibody for assessment of autoimmune disorder, any method | Office | 2023 | 79 | 644 | $32,060 | $11,222 | 35.0% |
| 86146 | Beta 2 glycoprotein 1 antibody (autoantibody) measurement | Office | 2023 | 78 | 276 | $14,400 | $6,822 | 47.4% |
| 86147 | Cardiolipin antibody (tissue antibody) measurement | Office | 2023 | 78 | 276 | $14,400 | $6,822 | 47.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 51 | 51 | $16,590 | $6,067 | 36.6% |
| 83520 | Measurement of substance using immunoassay technique | Office | 2023 | 79 | 361 | $11,665 | $6,042 | 51.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 54 | 81 | $12,825 | $5,398 | 42.1% |
| 73130 | X-ray of hand, minimum of 3 views | Office | 2023 | 59 | 127 | $7,620 | $3,876 | 50.9% |
| 73630 | X-ray of foot, minimum of 3 views | Office | 2023 | 54 | 120 | $9,000 | $3,442 | 38.2% |
| 20606 | Aspiration and/or injection of fluid from medium joint using ultrasound guidance | Office | 2023 | 20 | 41 | $7,250 | $3,140 | 43.3% |
| 20552 | Injection of trigger points, 1-2 muscles | Office | 2023 | 26 | 78 | $8,310 | $2,826 | 34.0% |
| 73030 | X-ray of shoulder, minimum of 2 views | Office | 2023 | 38 | 82 | $4,920 | $2,286 | 46.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 17 | 17 | $4,760 | $2,169 | 45.6% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 23 | 29 | $5,800 | $2,129 | 36.7% |
| 20553 | Injection of trigger points, 3 or more muscles | Office | 2023 | 20 | 43 | $5,910 | $2,006 | 33.9% |
| 83516 | Analysis of substance using immunoassay technique, multiple step method | Office | 2023 | 79 | 179 | $5,370 | $2,000 | 37.2% |
| 73562 | X-ray of knee, 3 views | Office | 2023 | 46 | 50 | $3,000 | $1,764 | 58.8% |
| 86800 | Thyroglobulin (thyroid protein) antibody measurement | Office | 2023 | 79 | 93 | $4,380 | $1,438 | 32.8% |
| 20604 | Aspiration and/or injection of fluid from small joint using ultrasound guidance | Office | 2023 | 14 | 24 | $3,770 | $1,434 | 38.0% |
| 86376 | Microsomal antibodies (autoantibody) measurement | Office | 2023 | 79 | 93 | $3,720 | $1,315 | 35.4% |
| 86225 | Measurement of dna antibody, native or double stranded | Office | 2023 | 79 | 94 | $3,730 | $1,256 | 33.7% |
| 86200 | Measurement of antibody for rheumatoid arthritis assessment | Office | 2023 | 79 | 93 | $3,580 | $1,171 | 32.7% |
| 86226 | Measurement of dna antibody, single stranded | Office | 2023 | 79 | 94 | $3,480 | $1,107 | 31.8% |
About Dr. Smitha Reddy, M.D
Dr. Smitha Reddy, M.D is a Rheumatology healthcare provider based in Poway, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/03/2008. The National Provider Identifier (NPI) number assigned to this provider is 1750534715.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Smitha Reddy, M.D has received a total of $255,784 in payments from pharmaceutical and medical device companies, with $8,126 received in 2024. These payments were reported across 1,334 transactions from 40 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($149,438).
As a Medicare-enrolled provider, Reddy has provided services to 6,671 Medicare beneficiaries, totaling 17,641 services with total Medicare billing of $744,214. Data is available for 4 years (2020–2023), covering 123 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Poway, CA
- Active Since 11/03/2008
- Last Updated 11/18/2020
- Taxonomy Code 207RR0500X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1750534715
Products in Payments
- TALTZ (Drug) $144,498
- TREMFYA (Drug) $9,221
- OLUMIANT (Drug) $7,864
- RAYOS (Drug) $5,711
- COSENTYX (Biological) $3,415
- XELJANZ (Drug) $3,184
- Otezla (Drug) $2,752
- Rasuvo (Drug) $2,640
- Crysvita (Drug) $1,902
- Enbrel (Biological) $1,708
- COSENTYX (Drug) $1,460
- STELARA (Biological) $1,318
- RINVOQ (Biological) $1,168
- BENLYSTA (Biological) $1,060
- ACTHAR (Biological) $915.00
- REMICADE (Biological) $883.44
- LUPKYNIS (Drug) $815.92
- KRYSTEXXA (Biological) $611.44
- SAPHNELO (Biological) $578.50
- SKYRIZI (Biological) $399.94
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.